deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03361306

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

LCI-HEM-MYE-CRD-002: A Phase II Study of Carfilzomib- Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Sponsor: Atrium Health Levine Cancer Institute

Conditions Multiple Myeloma
Interventions Elotuzumab
Updated 32 times since 2017 Last updated: Feb 12, 2026 Started: Jan 9, 2018 Primary completion: Jun 4, 2021 Completion: Feb 14, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Atrium Health Levine Cancer Institute and has accumulated 32 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~May 2019 · 5 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Jul 2023 · 4 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Feb 2024 · 6 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Aug 2025 · 3 months · monthly snapshot~Aug 2025 – ~Feb 2026 · 6 months · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

32 versions recorded

  1. Mar 2026 — Present [monthly]

    Completed PHASE2

  2. Feb 2026 — Mar 2026 [monthly]

    Completed PHASE2

  3. Aug 2025 — Feb 2026 [monthly]

    Completed PHASE2

  4. May 2025 — Aug 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Apr 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 27 earlier versions

  1. Feb 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  6. Aug 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  7. Jul 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

  8. Mar 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

  9. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  10. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  11. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  12. Feb 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  13. Dec 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  14. Nov 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  15. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  16. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  17. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  18. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  19. Mar 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  20. Sep 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  21. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  22. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  23. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  24. Dec 2018 — May 2019 [monthly]

    Recruiting PHASE2

  25. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  26. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  27. Dec 2017 — Jan 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Atrium Health Levine Cancer Institute
  • Bristol-Myers Squibb
  • Wake Forest University Health Sciences
Data source: Wake Forest University Health Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations